Company Overview
Snapshot
Founded in January 2015 by Amos Ziv and Tsahi Holand, CardiaCare operates with 11–50 employees. The company has raised $4.33 million across four funding rounds. In September 2023, CardiaCare completed an oversubscribed Seed Extension round, led by.
Business overview
CardiaCare is a clinical-stage Digital Therapeutic company specializing in non-invasive treatment for Atrial Fibrillation and other cardiac arrhythmias. Its core offering is a closed-loop wearable device that provides nerve stimulation treatment, continuous monitoring, and AI-based alerts. This platform enables comprehensive remote patient management and personalized treatment, serving the digital healthcare and medical devices sectors by offering innovative solutions for chronic cardiac conditions.
Strategic signal
In September 2023, CardiaCare successfully closed an oversubscribed Seed Extension round, with funds earmarked to expand the clinical program for its wearable technology. This investment, led by Solardis Health Ventures, signals strong investor confidence in CardiaCare's innovative approach to cardiac arrhythmia treatment and its potential to establish a new standard of care through remote patient management and personalized neuromodulation.
Log in to access full profile ›Company Intelligence Q&A
- What is CardiaCare's primary product?
- CardiaCare develops the world's first closed-loop wearable device for the non-invasive treatment of Atrial Fibrillation and other cardiac arrhythmias, integrating nerve stimulation with continuous monitoring and AI-based alerts.
- When did CardiaCare last raise funding and for what purpose?
- In September 2023, CardiaCare completed an oversubscribed Seed Extension round, led by. The capital is being used to expand the clinical program for its technology designed to treat Atrial Fibrillation and other cardiac arrhythmias.
- Has CardiaCare established any strategic partnerships for commercialization?
- In December 2022, CardiaCare entered into a strategic licensing and distribution agreement with Dr. Reddys Laboratories. This partnership aims to commercialize CardiaCare's digital neuromodulation wearable in India, with Dr. Reddys Laboratories leading clinical studies for regulatory clearance.
- Who was recently appointed to CardiaCare's board?
- In May 2023, CardiaCare appointed Ken Nelson as its board chair. Nelson brings two decades of experience in the medtech industry, with a focus on building sales, marketing, and commercialization teams, as the company ramps up multiple clinical trials.
- What recognition has CardiaCare received for its innovation?
- In December 2019, CardiaCare was awarded First Prize at the Innovation in Cardiovascular Interventions (ICI) Technology Parade in Tel Aviv, Israel, for its innovative wearable neuromodulation device for monitoring and treating Atrial Fibrillation.